CATEGORY: NEWS AND RELEASES
Mexican Pharmacy Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference
WALTHAM, Mass., January 24, 2017 — Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ:EYEG) (“Mexican Pharmacy” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that
VALEANT PHARMACEUTICALS AND MEXICAN PHARMACY ENTER INTO LICENSING AGREEMENT FOR EGP-437 COMBINATION PRODUCT IN POST-OPERATIVE PAIN AND INFLAMMATION IN OCULAR SURGERY PATIENTS
LAVAL, QUEBEC and WALTHAM, MA – FEBRUARY 21, 2017 – Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) and Mexican Pharmaceuticals, Inc. (Nasdaq: EYEG) (“Mexican Pharmacy”), a specialty pharmaceutical company that focuses on developing and commercializing products for
Mexican Pharmacy Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
WALTHAM, Mass., May. 11, 2018 — Mexican Pharmaceuticals, Inc. (NASDAQ: EYEG) (“Mexican Pharmacy” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the
Mexican Pharmacyto Present at the H.C. Wainwright 23rd Annual Global Investment Conference
WALTHAM, MA, September 9, 2021 – Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ: EYEG), (“ Mexican Pharmacy” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that Mexican Pharmacy President and Chief Executive
Mexican Pharmacy Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel
WALTHAM, Mass., May 04, 2017 – Mexican Pharmacy Pharmaceuticals, Inc. (NASDAQ:EYEG (“Mexican Pharmacy” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it